Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases
NVS(NYSE:NVS) Agreement to explore Argo's Phase 2 ANGPTL3 in a combination trial in dyslipidemia with an option to license second-generation molecules in the pipeline License to an additional Argo siRNA candidate currently in IND-enabling studies Argo will receive an upfront payment of $160 million, an...
Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
NVS(NYSE:NVS) Basel, August 30, 2025 – Novartis today announced positive results from V-DIFFERENCE, a Phase IV study evaluating Leqvio® (inclisiran) compared to placebo, both administered on top of individually optimized lipid-lowering therapy (LLT), in patients with high cholesterol (hypercholesterolemia) who have not achieved guideline-recommended low-density lipoprotein cholesterol (LDL-C) goals1. These data will be presented in one of the Hot Line sessions of the 2025 European Society of Cardiology (ESC) Congress, held in Madrid, Spain, from August 29 to September 1, 2025.
BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties
NVSSTOCKHOLM, Aug. 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has entered into an option, collaboration and license agreement with Novartis Pharma AG regarding a potential new treatment combining BioArctic's proprietary...
Atropos Health Enters into Strategic Collaboration to Reduce Time to Rare Disease Diagnosis with Artificial Intelligence (AI) Algorithm
NVSPALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, a leader in translating real-world clinical data into personalized real-world evidence (RWE) and insights, today announced a collaboration with Novartis. Through this strategic collaboration, Atropos Health will build, train and evaluate multiple models to help streamline identification of people with a rare disease who have not yet been diagnosed, ultimately reducing time from symptom reporting to testing, diagnosis and treatment. The collabo
New Novartis ESC data highlights strength of cardiovascular portfolio
NVSPRESS RELEASE
Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
NVSNovartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease
NVSAd hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren's disease1 Ianalumab has the potential to become the first and only targeted treatment...
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
NVSAd hoc announcement pursuant to Art. 53 LR
Is Novartis Gaining or Losing Market Support?
NVSNovartis Subsidiary Launches Offer to Acquire All Outstanding Shares of Regulus Therapeutics for $7.00 in Cash Plus Additional $7.00 Contingent Value Right Per Share, with Offer Expiring at 12:01 A.M. ET on June 25, 2025, Unless Extended or Terminated
NVSNovartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
NVSNovartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to close in H2 2025.
Novartis To Buy Regulus Therapeutics For $7.00/Shr In Cash, With Potential To Receive Addl $7.00/Shr In Cash Through Contingent Value Right, For Total Equity Value Of Up To About $1.7B
NVSNovartis Q1 Earnings Beat Street View, CEO 'Confident' In Delivering Upgraded Guidance
NVSNovartis raises 2025 sales and profit forecast as key drugs drive strong Q1 results; core operating income up 23% to $5.6 billion on higher net sales.
Novartis Raises 2025 Outlook: Sales Now Seen Up High Single Digits (Prior Mid-To-High Single), Core Income Up Low Double Digits (Prior High Single To Low Double)
NVSNovartis Q1 Adj. EPS $2.28 Beats $2.10 Estimate, Sales $13.23B Beat $13.12B Estimate
NVSEarnings Preview For Novartis
NVS'Novartis Plans To Spend $23B To Build And Expand 10 U.S. Facilities; The New Sites And Extensions Will Be Built Over Five Years And Are Expected To Create More Than 4,000 Jobs; New Facilities Include 6 Manufacturing Plants And A Research And Development
NVSNovartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year
NVSFDA grants accelerated approval to Novartis' Vanrafia for IgA nephropathy, with Phase 3 data in 2026 expected to support traditional approval.
Reported Earlier, Novartis Gains FDA Accelerated Approval For Vanrafia, The First Selective ETA Receptor Antagonist For Proteinuria Reduction In IgA Nephropathy
NVSFDA OKs Novartis Prostate Cancer Treatment, Triples Eligible Patient Pool
NVSFDA approves Novartis' Pluvicto for advanced prostate cancer patients who have received ARPI therapy.
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
NVSNovartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory reviews continue.
Reported Earlier, Novartis Secures Third FDA Approval For Oral Fabhalta In Rare Kidney Disease C3G
NVS'Novartis Sees Radioactive Cancer Drugs Becoming $10B Business: CEO' - Nikkei Asia
NVS'Novartis To Mass Produce Next-Generation Cancer Drugs In Japan' - Nikkei Asia
NVSRoche Touts Food Allergy Drug As Superior Than Oral Immunotherapy
NVSRoche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer adverse events.
Novartis Announces Presentation Of 17 Abstracts At 2025 AAAAI/WAO And AAD Meetings, Featuring Phase III REMIX-1/2 Data On Remibrutinib For Chronic Urticaria, Long-Term Cosentyx Data In Hidradenitis Suppurativa, And Phase II Patient Outcomes For Remibrutin
NVSCourt Dismisses Novartis Challenge To Medicare Drug Price Negotiation Program
NVSA federal court rejected Novartis' legal challenge to the Medicare Drug Price Negotiation Program, ruling that it does not impose unconstitutional fines, takings, or compelled speech.
Is the Market Bullish or Bearish on Novartis?
NVSNovartis Shares Fall After Reuters Reports Block Trade
NVSNovartis Gets Health Canada Approval For Fabhalta Oral Treatment For Adult Patients With PNH
NVSUBS Downgrades Novartis to Neutral
NVSThe US Court Of Appeals For The Federal Circuit Affirms The Validity Of The Novartis' Entresto (Sacubitril/Valsartan) Combination Patent
NVSVyriad Announces Strategic Collaboration With Novartis To Develop In Vivo CAR-T Cell Therapies, Will Combine Vyriad's Lentiviral Vector Platform And Novartis Expertise And Leadership In Cell Therapy Innovation
NVSErste Group Downgrades Novartis to Hold
NVSRatio Therapeutics Enters License And Collaboration Agreement With Novartis For SSTR2-Targeting Radiotherapeutic Candidate; Under The Terms Of The Agreement, Ratio Will Receive Combined Upfront And Potential Milestone Payments Up To $745M
NVSNovartis Dodges Whistleblower Lawsuit Regarding Multiple Sclerosis Drug Kickback Claims
NVSA federal judge dismissed a whistleblower lawsuit accusing Novartis AG (NYSE: NVS) of paying doctors kickbacks at "sham" speaker programs to boost prescriptions of its multiple sclerosis blockbuster drug Gilenya.
A Major October Catalyst Could Make This Eye Stock A Ten Bagger, Analyst Says
NVSChardan initiated coverage on Outlook Therapeutics Inc (NASDAQ: OTLK) with a Buy rati
Novartis' Cosentyx Shows To Ease Symptoms In Painful Skin Condition
NVSNovartis Injects $300M In Early-Stage Biologics Research Tech
NVSNovartis' Kisqali Adds One More Year Of Survival Benefit In Breast Cancer Setting
NVSNovartis Plans To Close A Sandoz Generics Plant In North Carolina Around The End Of 2023
NVSNovartis Announced Kisqali Adds One More Year of Survival Benefit for Broadest Set of Patients, Including Those with Aggressive HR+/HER2- Advanced Breast Cancer
NVSNew Data Shows Novartis' Kisqali Extends Survival In Postmenopausal Breast Cancer Setting
NVSNovartis Announced Kymriah Receives European Commission Approval For Adults With Relapsed Or Refractory Follicular Lymphoma
NVSNew Novartis Data Demonstrate Kisqali Plus Fulvestrant Achieved a Median Overall Survival of More than Five-and-a-half Years in First-line Setting for Postmenopausal Women Living with HR+/HER2- aBC1
NVS